Dusp6-flox Mouse
Common Name
Dusp6-flox
제품 ID
S-CKO-13779
Backgroud
C57BL/6JCya
품종 계통계통 ID
CKOCMP-67603-Dusp6-B6J-VA
상태
이 마우스 계통을 논문에서 사용할 경우, “Dusp6-flox Mouse (카탈로그 번호 S-CKO-13779)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
표준 제공 조건은 최소 3마리의 이형접합(heterozygous) 보균자를 보장합니다. 동형접합(homozygous) 보균자 및/또는 특정 성별에 대한 브리딩 서비스도 제공됩니다.
기본 정보
품종 계통
Dusp6-flox
품종 계통계통 ID
CKOCMP-67603-Dusp6-B6J-VA
유전자명
제품 ID
S-CKO-13779
유전자 별칭
MKP3, MKP-3, PYST1, 1300019I03Rik
배경
C57BL/6JCya
NCBI ID
변형 내용
Conditional knockout
염색체
Chr 10
Phenotype
Datasheet
적용 분야
--
품종 계통 설명
Ensembl 전사체 ID
ENSMUST00000020118
NCBI 전사체 ID
NM_026268
타겟 영역
Exon 1~2
유효 영역 크기
~2.0 kb
유전자 연구 개요
Dusp6, also known as MKP3, is a dual-specificity phosphatase with a conserved function in the dephosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) [2]. It is involved in multiple signaling pathways, including the MAPK pathway, and plays a crucial role in various biological processes, such as cell proliferation, differentiation, and inflammation [1,2,4]. Genetic models, like knockout mouse models, have been instrumental in studying its functions.
In myeloproliferative neoplasms (MPNs) transforming to secondary acute myeloid leukemia (sAML), Dusp6 expression is aberrantly increased. Pharmacologic targeting of Dusp6 inhibits S6 and JAK-STAT signaling, reduces inflammatory cytokine production, and suppresses disease development in MPN mouse models and sAML patient-derived xenografts (PDXs) [1].
In the context of myocardial infarction, Dusp6 deficiency attenuates neutrophil-mediated cardiac damage in the acute inflammatory phase. Mechanistically, Dusp6 is transcriptionally activated by p38-C/EBPβ signaling and maintains p-p38 activity [2].
In HER2+ breast cancer, Dusp6 expression is induced during re-proliferation from dormant drug-tolerant cells. Its pharmacological blockade prevents therapy tolerance development under HER2 inhibitor therapy [3].
In MAPK pathway-driven cancers, dual inactivation of Dusp4 and Dusp6 impairs the growth of NRAS and BRAF mutant cells [4].
In colorectal cancer, Dusp6 can dephosphorylate Notch1, regulating its stability and transcriptional activity, and promoting cancer cell proliferation [5].
In colon cancer, PKN2 can inhibit M2 phenotype polarization of tumor-associated macrophages via regulating the Dusp6-Erk1/2 pathway [6].
Mutations in Dusp6 are identified in individuals with congenital hypogonadotropic hypogonadism [7].
Dusp6 deficiency attenuates neurodegeneration after global cerebral ischemia, as Dusp6 is induced in hippocampal CA1 neurons after ischemia, and its deficiency enhances Erk1/2 phosphorylation and nuclear translocation [8].
In Xenopus, Dusp6 is required for pre-placodal ectoderm formation by mediating FGF signaling [9].
In renal cell carcinoma, diminished Dusp6 expression is linked to disease progression, and calcium saccharate can enhance Dusp6 expression, inhibiting tumor cell proliferation and metabolic rewiring [10].
In conclusion, Dusp6 is a key regulator in multiple biological processes, mainly through its function in dephosphorylating ERK1/2. The use of Dusp6 knockout or conditional knockout mouse models has revealed its significance in diseases such as hematological malignancies, cardiovascular diseases, breast cancer, various cancers, neurodegenerative diseases, and developmental processes. Understanding Dusp6 provides potential therapeutic targets for these diseases.
References:
1. Kong, Tim, Laranjeira, Angelo B A, Yang, Kangning, Huang, Sidong, Oh, Stephen T. 2022. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression. In Nature cancer, 4, 108-127. doi:10.1038/s43018-022-00486-8. https://pubmed.ncbi.nlm.nih.gov/36581736/
2. Zhou, Xiaohai, Zhang, Chenyang, Wu, Xueying, Zhu, Xiaojun, Xiong, Jing-Wei. 2022. Dusp6 deficiency attenuates neutrophil-mediated cardiac damage in the acute inflammatory phase of myocardial infarction. In Nature communications, 13, 6672. doi:10.1038/s41467-022-33631-z. https://pubmed.ncbi.nlm.nih.gov/36335128/
3. Momeny, Majid, Tienhaara, Mari, Sharma, Mukund, Kurppa, Kari J, Westermarck, Jukka. 2024. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. In EMBO molecular medicine, 16, 1603-1629. doi:10.1038/s44321-024-00088-0. https://pubmed.ncbi.nlm.nih.gov/38886591/
4. Ito, Takahiro, Young, Michael J, Li, Ruitong, Zamanighomi, Mahdi, Sellers, William R. 2021. Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. In Nature genetics, 53, 1664-1672. doi:10.1038/s41588-021-00967-z. https://pubmed.ncbi.nlm.nih.gov/34857952/
5. Png, Chin Wen, Weerasooriya, Madhushanee, Li, Heng, Tan, Ker-Kan, Zhang, Yongliang. 2024. DUSP6 regulates Notch1 signalling in colorectal cancer. In Nature communications, 15, 10087. doi:10.1038/s41467-024-54383-y. https://pubmed.ncbi.nlm.nih.gov/39572549/
6. Cheng, Yang, Zhu, Yun, Xu, Jiajia, Geng, Lanlan, Gong, Sitang. 2018. PKN2 in colon cancer cells inhibits M2 phenotype polarization of tumor-associated macrophages via regulating DUSP6-Erk1/2 pathway. In Molecular cancer, 17, 13. doi:10.1186/s12943-017-0747-z. https://pubmed.ncbi.nlm.nih.gov/29368606/
7. Miraoui, Hichem, Dwyer, Andrew A, Sykiotis, Gerasimos P, Lage, Kasper, Pitteloud, Nelly. . Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism. In American journal of human genetics, 92, 725-43. doi:10.1016/j.ajhg.2013.04.008. https://pubmed.ncbi.nlm.nih.gov/23643382/
8. Weng, Yi-Chinn, Huang, Yu-Ting, Chiang, I-Chen, Tan, Tse-Hua, Chou, Wen-Hai. 2023. DUSP6 Deficiency Attenuates Neurodegeneration after Global Cerebral Ischemia. In International journal of molecular sciences, 24, . doi:10.3390/ijms24097690. https://pubmed.ncbi.nlm.nih.gov/37175394/
9. Tsukano, Kohei, Yamamoto, Takayoshi, Watanabe, Tomoko, Michiue, Tatsuo. 2022. Xenopus Dusp6 modulates FGF signaling to precisely pattern pre-placodal ectoderm. In Developmental biology, 488, 81-90. doi:10.1016/j.ydbio.2022.05.009. https://pubmed.ncbi.nlm.nih.gov/35598626/
10. Liu, Huan, Wang, Longsheng, Shi, Xiaokai, Chen, Yonghui, Zhang, Tao. 2024. Calcium saccharate/DUSP6 suppresses renal cell carcinoma glycolytic metabolism and boosts sunitinib efficacy via the ERK-AKT pathway. In Biochemical pharmacology, 224, 116247. doi:10.1016/j.bcp.2024.116247. https://pubmed.ncbi.nlm.nih.gov/38697311/
품질 관리 기준
정자 검사
동결 보존 전: 정자 농도 측정 및 정자 생존율 평가.
동결 보존 후: 각 배치에서 동결 보존된 정자 바이알 1개를 선택하여 체외수정(in vitro fertilization)에 사용합니다.
Environmental Standards:
SPFAvailable Region:
GlobalSource:
Cyagen문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.
